Regeneron Pharmaceuticals, Inc (REGN)

Etorro trading 970x250
Regeneron Pharmaceuticals, Inc (REGN) Logo

About Regeneron Pharmaceuticals, Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it offers Inmazeb injection for infection caused by Zaire ebolavirus; and develops product candidates for treating patients with eye, allergic and inflammatory, cancer, cardiovascular and metabolic, pain, infectious, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and Biomedical Advanced Research Development Authority. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York. Address: 777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707

Regeneron Pharmaceuticals, Inc News and around…

Latest news about Regeneron Pharmaceuticals, Inc (REGN) common stock and company :

Vaccines 'still the backbone of everything we do' amid any variants, doctor explains
26 Nov, 2021 Yahoo! Finance

ICU physician Dr. Lakshman Swamy, from Cambridge Health Alliance and Boston Medical Center, speaks on Yahoo Finance Live about the new reports of a surge in cases involving COVID-19. and importance of vaccines.

Stocks fall, Merck drops on COVID-19 pill effectiveness, air travel hits pandemic high, more PPP fraud
26 Nov, 2021 Yahoo! Finance

Yahoo Finance's Seana Smith details some headlines that we are watching on Friday.

'Travel bans don't work,' doctor explains amid reports of newly discovered variant
26 Nov, 2021 Yahoo! Finance

Dr. Amesh A. Adalja MD, a senior scholar at the Johns Hopkins Center for Health Security, joins Yahoo Finance Live to discuss the newly discovered COVID-19 variant and the potential implications based on what is currently known.

Stocks down after discovery of new COVID-19 variant
26 Nov, 2021 Yahoo! Finance

Stock market futures dropped on Friday amid uncertainty about a newly discovered COVID-19 variant.

Are Robust Financials Driving The Recent Rally In Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Stock?
25 Nov, 2021 Yahoo! Finance

Regeneron Pharmaceuticals (NASDAQ:REGN) has had a great run on the share market with its stock up by a significant 12...

Drugmakers Gear Up for Price Restrictions in Biden’s Legislative Agenda
25 Nov, 2021 Yahoo! Finance

The industry potentially faces a significant expansion of government regulation despite success in watering down Democratic proposals in the social-spending and climate bill.

Her mission at Regeneron: Connection, then reflection
24 Nov, 2021 Yahoo! Finance

Meylin Andares helped increase the applicant pool for Black and Latino students by nearly 45% during the 10 years she spent recruiting for the University at Albany, her alma mater. Then a phone call from her best friend, who is part of the legal team at Regeneron Pharmaceuticals in North Greenbush, prompted Andares to pursue a newly created position for the drug developer’s manufacturing and product supply team: director of diversity, equity and inclusion. Within a month, Andares finished her master’s degree in higher education administration from Stony Brook University.

The Petri Dish: $2.5M for another Bob Langer startup, Decibel extends Regeneron deal
24 Nov, 2021 Yahoo! Finance

While some in the life sciences industry create drugs and devices to tackle the Covid-19 pandemic, their colleagues are busy as ever raising money, testing new drugs, expanding facilities and more. Here's The Petri Dish, a roundup of news that may get overlooked amid the influx of Greater Boston life sciences and health care happenings.

Ones To Watch: Novavax Stock Sees RS Rating Jump To 85
23 Nov, 2021 FinancialContent

Novavax sees its Relative Strength Rating reach the 80-plus level.

Countries pushing vaccine IP waivers ‘want to take advantage of the technology’: Fmr. U.S. Commerce Secretary
23 Nov, 2021 Yahoo! Finance

Former U.S. Commerce Secretary and Former Washington Governor Gary Locke joins Yahoo Finance Live to discuss travel warnings to Germany and Denmark as COVID-19 cases are rising, the push get more vaccinated in developing countries, and the impact of Trump's tariffs on Chinese goods.

Biotech Stocks are Due for a Rally
22 Nov, 2021 FinancialContent

There are many rebalancing trades left in your stock portfolio but biotech is in the doldrums.

Regeneron Extends Hearing Loss Gene Therapy pact With Decibel
22 Nov, 2021 FinancialContent

Regeneron Pharmaceuticals Inc(NASDAQ: REGN) hasextended the research term of its collaborationwithDecibel ...

Why Regeneron's Results for Its COVID Antibody Therapy Won't Boost Sales Much
20 Nov, 2021 FinancialContent

The therapy will likely face stiff competition from more convenient COVID-19 pills.

Is Merck Stock a Buy?
20 Nov, 2021 FinancialContent

The company's financial results are rebounding from their pandemic lows.

Why Connect Biopharma Stock Is Crashing Today
19 Nov, 2021 FinancialContent

Investors wanted more details from the company's latest clinical results.

The Daily Biotech Pulse: Connect Biopharma Sinks On Eczema Drug Readout, Enanta Pulls Plug On HBV Drug, Clinical Setback For Merck In HIV Trial
19 Nov, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Connect Biopharma Atopic ...

'Everyone is a little bit confused' about COVID-19 vaccine mandates and rules: Doctor
18 Nov, 2021 Yahoo! Finance

Dr. James Simmons, Hospitalist Nurse Practitioner joins Yahoo Finance’s Alexis Christoforous to discuss on holiday gatherings amid rising COVID-19 cases and the potential "double whammy" amid flu season.

Glaxo (GSK), Vir to Supply COVID Drug Sotrovimab to Government
18 Nov, 2021 Yahoo! Finance

Glaxo (GSK) and Vir Biotechnology (VIR) sign purchase contract with the U.S. government to supply doses of sotrovimab worth approximately $1 billion by next month.

The Biggest Problem With Moderna Has Nothing to Do With Its Recent Earnings Miss
18 Nov, 2021 FinancialContent

Its future is full of question marks.

Stocks Most Impacted by 7-10 Year Treasuries
17 Nov, 2021 FinancialContent

A look at S&P 500 members that perform best when the iShares 7-10 Year Treasury Bonds ETF (IEF) loses value.

'There will be another pandemic' and we need to be prepared when it comes: Doctor
17 Nov, 2021 Yahoo! Finance

Emergency Medicine Physician Dr. Hiral Tipirneni speaks with Yahoo Finance’s Alexis Christoforous and Karina Mitchell about how Americans must still take precautions when spending their holidays indoors with family amid the ongoing pandemic. 

Biotech Stock Roundup: REGN Gets EC Nod for Cocktail, BIIB's Drug Approval & More
17 Nov, 2021 Yahoo! Finance

Drug approvals for Regeneron (REGN) and Biogen (BIIB) have been the biotech sector's few key highlights during the past week.

Pfizer (PFE) Seeks FDA's Emergency Use Nod for COVID Pill
17 Nov, 2021 Yahoo! Finance

Pfizer's (PFE) COVID-19 pill reduces hospitalizations and deaths substantially in mild-to-moderate COVID-19 patients at increased risk of hospitalizations or death.

Glaxo and Vir Report $1 Billion Sale of Covid-19 Antibody. The U.S. Is Still Buying.
17 Nov, 2021 Yahoo! Finance

Sellers of monoclonal antibodies have seen their share prices take a hit since Merck and Pfizer announced positive data on Covid-19 antiviral pills.

Regeneron Announces Investor Conference Presentations
16 Nov, 2021 Yahoo! Finance

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:

COVID-19 booster shots are 'going to be the norm,' NewYork-Presbyterian Hospital CEO explains
16 Nov, 2021 Yahoo! Finance

NewYork Presbyterian Hospital CEO Dr. Steven Corwin joins Yahoo Finance to discuss the latest related to booster shots against COVID-19.

IBD Rating Upgrades: Regeneron Pharmaceutical Shows Improved Relative Price Strength
16 Nov, 2021 FinancialContent

A Relative Strength Rating upgrade for Regeneron Pharmaceutical shows improving technical performance. Will it continue?

Regeneron (REGN), Roche Get EC Nod for COVID-19 Cocktail
15 Nov, 2021 Yahoo! Finance

Regeneron (REGN) and partner Roche win the European Commission's approval for antibody cocktail to treat and prevent COVID-19.

A Peek Into The Markets: US Stock Futures Higher Ahead Of Tyson Foods Earnings
15 Nov, 2021 FinancialContent

Pre-open movers U.S. stock futures traded higher in early pre-market trade after closing higher in the prior session. Investors are ...

5 Stocks To Watch For November 15, 2021
15 Nov, 2021 FinancialContent

Some of the stocks that may grab investor focus today are: Wall Street expects Warner Music Group Corp. (NYSE: WMG) to report ...

Regeneron Pharmaceuticals, Inc (REGN) is a NASDAQ Common Stock listed in , ,

970x250